Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS - Test2 - elhamkhani - TriplyDB

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

http://www.wikidata.org/entity/Q24683100

about

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss Is lipid signaling through cannabinoid 2 receptors part of a protective system?Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.The endocannabinoid system as an emerging target of pharmacotherapy Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers Novel cannabinoid receptors Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation Therapeutic potential of monoacylglycerol lipase inhibitors Expression Analysis of CB2-GFP BAC Transgenic Mice The CB2 receptor and its role as a regulator of inflammation Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer Targeting cannabinoid agonists for inflammatory and neuropathic pain Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.Recent data on cannabinoids and their pharmacological implications in neuropathic pain.Targeted zwitterionic near infrared fluorescent probe for improved imaging of type 2 cannabinoid receptors.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective Forced exercise attenuates neuropathic pain in chronic constriction injury of male rat: an investigation of oxidative stress and inflammation Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.CB2: a cannabinoid receptor with an identity crisis Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain Pathogenesis of spinal cord injury induced edema and neuropathic pain: expression of multiple isoforms of wnk1.Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2.Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal

P2860

Q24556619-2582DA51-5669-461C-87A9-3EAB8FA2D3F9 Q24564956-02B95EA3-D546-459C-A75D-9D1F474ED5AD Q24615787-823F5311-E782-4C79-A560-27379676A17D Q24633122-FA48790D-4FF3-4C34-80C7-93D1544B0FEA Q24634161-0B2C2AAD-0167-41AB-9557-05E6EF200B8B Q24643672-461C5D86-65A6-483F-BA52-D5D89B2BEC7B Q24643941-5EE242FB-40A0-47A8-8ACC-89EDDAFCF10E Q24643957-A23F0A02-02BA-42E5-9672-2F07240E36DF Q24648473-66C5B6E3-9D41-4B67-A609-962B0B7C2B77 Q24673335-63AE115E-9D4F-4BF6-8CD3-ADA832177ACE Q24681482-F50B43BE-C968-40C2-8F17-A318D9BE47E5 Q26829111-A23029E7-A35F-42E7-9BF3-02F5CC7C2C29 Q26991513-92712007-0198-4415-A26D-FE1D85F6E26D Q27316448-59C82293-3F4C-45F0-A652-A95A6F49F8BF Q28066700-4C274428-47E0-4714-8E19-376AA82D9506 Q28241318-52C0D78E-1228-4F89-9931-3D3F8F186D74 Q28248981-87E87980-AEA5-474C-B2B3-5011B8B7EA45 Q28304230-C4585A4E-597D-4F73-B7D1-199EF133CF74 Q28307619-85155B34-BB9A-4A39-9831-25AD6E487C77 Q28472191-40062417-60A7-4790-BF27-20FE2B678926 Q28480387-B4CA8BC5-AC68-4B9F-9A89-DB68B7AB9446 Q28566269-FBF11748-B6BF-41D8-8137-53BECABBE80E Q30473707-791273E5-46E9-4570-8212-A93CF6400CC0 Q33235278-2BBE3D0B-419D-432E-9FB5-0EB6C38A48E2 Q33527067-3385E1EB-C73D-4997-BC90-08EDEB8CEFDB Q33604098-01818D00-C8E1-4912-A129-D70C3085670A Q33664105-099D90C5-4CC2-4E81-BCAC-A4AFC6B6ACD0 Q33749455-85C91B4B-F0AC-42E1-A1A6-F444488D6B4B Q33781776-311BC4F6-C7F8-405D-8C51-4E6E4E955E86 Q33879278-AA1C6BC5-76F1-4062-BC66-34A64F3F7DBA Q34019573-13F75A21-AD6B-4739-A5F9-65449C73C4F8 Q34059803-7AEEEF5E-38CD-44C5-9F9A-EBD24FA81959 Q34098185-981D1F28-F48F-46E8-B11D-4B66AF4D4A4A Q34118976-B2CF84C2-F61E-4F69-9E29-A06E2C7D6C43 Q34153895-2C9245D5-6D27-48B6-8B0E-CBFD6A43A5FF Q34158418-FBFFD8C5-7652-48B5-A39E-C5F4EB976BF1 Q34176058-1F56C29B-01AF-492B-ADA3-60603F9F2C31 Q34186015-1B77919A-C5CE-48E9-90F9-879715C6CC7B Q34298682-43EE0A13-0F99-4170-83DD-BEB9D78C20EA Q34403197-AE134181-2A0A-4CEE-839D-281AB0FAA661

P2860

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

http://www.wikidata.org/entity/Q24683100

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@ast

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@en

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@nl

type

label

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@ast

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@en

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@nl

prefLabel

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@ast

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@en

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@nl

P1433

Q24683100-21C42D18-FBBE-4002-A9B2-49CD15CAFE47

P1476

Q24683100-5B582A0D-4D84-4724-83E0-2CED39CE5F56

P2093

Q24683100-0764475D-18AA-4791-AB46-8CB50EDB5399

Q24683100-60B3D93E-FBCE-4CCB-BBFA-FE32C65BE374

Q24683100-61269327-4B32-466E-9330-A9659547F65D

Q24683100-722DE534-D31C-4862-9A4A-6AF181E4B6FD

Q24683100-73D6B474-A4AD-4568-ACB0-57BF82C12D3E

Q24683100-9642C990-F509-4EBA-BD75-21AB492DFE32

Q24683100-B16FC59A-36DD-42E0-8BD9-C71C41DF6B20

Q24683100-C5356A0B-247B-43E1-ACE9-2B959AAF3CCA

P2860

Q24683100-0028C52A-722C-4752-8937-DA20D783A3B9

Q24683100-00F28FDF-F5DB-4175-82EA-FA71332F0EE6

Q24683100-04CCC509-A59B-4E24-B946-54FFD1D36A3F

Q24683100-05D22180-79F9-4CAD-82BD-4B188B6724BA

Q24683100-0ADFE41F-4133-4D66-A18A-F62F9B6906CF

Q24683100-0B3DDF14-92E6-4535-8E8F-D91F6D3BD981

Q24683100-1072B91E-D548-4B40-A7B0-DCFFBC40544C

Q24683100-26CFCA4A-5E5A-449A-B167-BDDD2E05C43C

Q24683100-3ACBD483-4177-4434-899C-CEA1B3DEE23C

Q24683100-5BF8DD92-F21E-494D-BFF8-DB44F3AE40FA

P304

Q24683100-03226665-CCCA-4A9C-8170-110EC71C3D7B

P31

Q24683100-1BC20C0A-E76D-4BCF-A7D1-74A04DE0ADC2

P3181

Q24683100-CBF48861-EAED-47E0-AF41-C8B1DB198B6E

P356

Q24683100-37AA5491-3933-42F3-B93B-971ED67E07F5

P407

Q24683100-924EBFE9-CDE1-48E7-B5E3-C49ADF7A2E4E

P433

Q24683100-D94A9EA7-04BE-485D-8E11-00E810EDCBCD

P478

Q24683100-64F4FEDC-7A62-4919-8E8E-7E195B44B82B

P50

Q24683100-24980B3F-9281-4729-9B77-BD489FBA1A94

Q24683100-602C93ED-50F8-4961-B92C-F87459239B68

Q24683100-C1834A2A-8059-4D2C-AEAA-F741CB39EF1C

P577

Q24683100-2E43ACA5-A7D7-4F4B-868C-68A8B063B8DE

P5875

Q24683100-30BEB33F-47B8-427E-B272-1DEFC5C5E3F7

P698

Q24683100-B8D69A53-1A6F-4A2A-A07C-3FDBB9BEB95F

P921

Q24683100-1E995316-50B4-425A-AD76-9CC2565153EA

Q24683100-5460131e-ed68-4645-bcd3-19d641f92cb1

Q24683100-A1DE87B3-F9B1-4E74-AB08-F1B9EAC51FED

Q24683100-E6BCA35B-52A7-49E2-8D30-D39496CB8774

P932

Q24683100-E9D10CEB-8090-4617-B283-C4EB40841518

P3181

P356

PNAS.1834309100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Activation of CB2 cannabinoid ...... ceptors not present in the CNS

@en

P2093

Alexander Zvonok

http://www.w3.org/2001/XMLSchema#string

Debra A Cockayne

http://www.w3.org/2001/XMLSchema#string

Heriberto P Mata

http://www.w3.org/2001/XMLSchema#string

Hongfeng Deng

http://www.w3.org/2001/XMLSchema#string

Joyce Kwan

http://www.w3.org/2001/XMLSchema#string

Mohab M Ibrahim

http://www.w3.org/2001/XMLSchema#string

T Philip Malan

http://www.w3.org/2001/XMLSchema#string

Todd W Vanderah

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

Quantitative assessment of tactile allodynia in the rat paw

A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia

Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model).

P304

10529-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2275801

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1834309100

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Alexandros Makriyannis

P577

2003-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10613743

http://www.w3.org/2001/XMLSchema#string

P698

12917492

http://www.w3.org/2001/XMLSchema#string

P921

neuropathic pain

cannabinoid receptor

P932

193595

http://www.w3.org/2001/XMLSchema#string